Effect of Renshen Yangying Decoction Combined with Chemotherapy on Traditional Chinese Medical Symptoms and T Cell Subsets in Patients with Cervical Cancer of Ganyu Qizhi Type
DOI:
https://doi.org/10.62767/jecacm304.3789Keywords:
Renshen Yangying decoction, Chemotherapy, Cervical cancer, Traditional Chinese medical syndrome, T cell subsetsAbstract
Background To confirm the effects of the combination of Renshen Yangying decoction and chemotherapy on traditional Chinese medical symptoms and T cell subsets in patients with cervical cancer (CC) of Ganyu Qizhi type.Methods: Patients with CC of Ganyu Qizhi type admitted to our hospital (n=96) were selected and evenly divided into control and observation groups. The patients in control group received chemotherapy, while those in observation group were additionally treated with Renshen Yangying decoction. The clinical efficacy, traditional Chinese medical symptom (TCMS) score, serum tumor markers, changes of serum T lymphocyte subsets and adverse effects were compared.Results: The distribution of clinical efficacy grade in all patients after treatment was statistically significant, and the clinical benefit rate (CBR) of observation group was higher than that of control group. The TCMS score, the serum carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCCA), and cancer antigen 125 (CA125) were also decreased after treatment, and those were decreased in observation group. Levels of serum CD4+ and CD4+/CD8+, and natural killer (NK) cell percentage were higher, yet serum CD8+ cell percentage was lower after treatment, and in patients of observation group, levels of serum CD4+ and CD4+/CD8+, and NK cell percentage were higher, yet serum CD8+ cell percentage was lower. The incidence of adverse effects in the observation group was lower than that in the control group.Conclusion: Renshen Yangying decoction combined with chemotherapy in the treatment of CC of Ganyu Qizhi type can alleviate the clinical symptoms, reduce serum tumor markers, and improve the cellular immunity, with significant clinical efficacy and good safety on patients.
Downloads
Published
Data Availability Statement
The analyzed data sets generated during the study are available from the corresponding author on reasonable request.Issue
Section
License
Copyright (c) 2022 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.